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Prostate cancer antigen 3 (PCA3) is the most specific prostate can-
cer biomarker but its function remains unknown. Here we identify
PRUNE2, a target protein-coding gene variant, which harbors the
PCA3 locus, thereby classifying PCA3 as an antisense intronic long
noncoding (lnc)RNA. We show that PCA3 controls PRUNE2 levels
via a unique regulatory mechanism involving formation of a
PRUNE2/PCA3 double-stranded RNA that undergoes adenosine de-
aminase acting on RNA (ADAR)-dependent adenosine-to-inosine RNA
editing. PRUNE2 expression or silencing in prostate cancer cells de-
creased and increased cell proliferation, respectively. Moreover,
PRUNE2 and PCA3 elicited opposite effects on tumor growth in immu-
nodeficient tumor-bearing mice. Coregulation and RNA editing of
PRUNE2 and PCA3 were confirmed in human prostate cancer speci-
mens, supporting the medical relevance of our findings. These results
establish PCA3 as a dominant-negative oncogene and PRUNE2 as an
unrecognized tumor suppressor gene in human prostate cancer, and
their regulatory axis represents a unique molecular target for diagnos-
tic and therapeutic intervention.
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Several lines of evidence demonstrate that long noncodingRNAs (lncRNAs) are functional in carcinogenesis through
regulatory mechanisms such as promoter looping, alternative splic-
ing, antisense gene silencing, transcriptional regulation, and DNA
repair, thus potentially serving as tumor markers. A few lncRNA
species have emerged as potential prostate cancer biomarkers such
as prostate cancer gene expression marker-1 (PCGEM1) and prostate
cancer noncoding RNA1 (PRNCR1), which enhance androgen re-
ceptor (AR)-dependent gene activation, and prostate cancer-associ-
ated ncRNA transcript-1 (PCAT1), which silences BRCA2 via
posttranscriptional homologous recombination (1). Notably, the
most specific biomarker in human prostate cancer identified to date
is an lncRNA, prostate cancer antigen 3 (PCA3, also known as
PCA3DD3 or DD3PCA3), which is up-regulated in human prostate
cancer (2). Since its discovery more than 15 y ago, PCA3 has been
extensively investigated (3) and has been approved for clinical ap-
plications to aid the diagnosis of prostate cancer in both the Eu-
ropean Union and the United States. Paradoxically—despite its
striking clinical specificity—the inherent cellular role of the
lncRNA PCA3 in human prostate cancer, if any, remains com-
pletely unknown (1). Here we report a unique biological function
for PCA3. Within a single functional genetic unit, we show that
PCA3 is an antisense intronic lncRNA that down-regulates an as yet
unrecognized tumor suppressor gene, a human homolog of the
Drosophila prune gene, PRUNE2, through a process that involves
RNA editing mediated by a supramolecular complex containing
adenosine deaminase acting on RNA (ADAR) family members. We
propose a working model in which PCA3 acts as a dominant-negative
oncogene in prostate cancer and show consistent results in thera-
peutic preclinical models and in patient-derived human samples.
Therefore, the molecular interaction of PRUNE2 and PCA3 is a
candidate target for translational applications.
Results
PCA3 Is an Antisense Intronic lncRNA Within a Single PRUNE2
Transcriptional Unit. Certain mammalian lncRNAs are embedded
in the intronic-antisense regions of protein-coding genes (4–6).
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PCA3 is a spliced intronic antisense lncRNA embedded within
intron 6 of the corresponding sense gene PRUNE2 (2, 7–10) (Fig.
1A). We hypothesized the existence of a functional role between
PCA3 and PRUNE2, and their involvement in prostate cancer
progression. To study this possibility, we investigated PRUNE2 as
well as the PCA3 intronic antisense transcripts, which we cloned
from MDA-PCa-133, a patient-derived xenograft (PDX) of bone
metastasis from prostate cancer (11) (Fig. 1 A and B). We next
analyzed the expression of PRUNE2 in representative panels of
human tumors and nonmalignant cell lines by quantitative gene
expression profiling with primers located in the PRUNE2 exons
that flank PCA3 (Tables S1 and S2 and Fig. S1 A and B). PRUNE2
was detectable in prostate cancer cell lines, with the highest levels
in androgen-dependent (LNCaP) cells, as well as in several brain
and breast lines. We also analyzed PRUNE2 levels alongside
PCA3 lncRNA in prostate cancer cells and observed differential
expression of the two genes: LNCaP cells displayed the highest levels
of both PRUNE2 and PCA3 relative to androgen-independent
(DU145 and PC3) cells (Fig. S1C). We confirmed the expression of
native or recombinant V5-tagged PRUNE2 by immunoblot analysis,
and the predicted endogenous protein (∼337 kDa) was observed in
LNCaP but not in PC3 cells (Fig. S1 D and E).
PCA3 lncRNA Binds PRUNE2 Pre-mRNA and Regulates Its Levels.
Given that PCA3 is embedded within intron 6 of PRUNE2,
and is transcribed in the antisense direction, we hypothesized
that a double-stranded (ds)RNA forms between PCA3 lncRNA
and PRUNE2 pre-mRNA to regulate PRUNE2 levels in prostate
cancer. To evaluate this possibility, we first generated prostate
cancer cell lines (LNCaP and PC3) stably transduced with ec-
topic PCA3, PCA3-shRNA, ectopic PRUNE2, PRUNE2-shRNA,
or the corresponding controls. Levels of endogenous PRUNE2
protein, pre-mRNA and mRNA increased with PCA3 silencing
and decreased with ectopic PCA3 expression (Fig. 1 C and D and
Fig. S1 F–H). We confirmed these findings in prostate- and
prostate cancer-derived cells, where ectopic PCA3 expression
induced down-regulation of endogenous PRUNE2 expression
(Fig. S2A). To determine whether PRUNE2 and PCA3 form a
dsRNA, we used co-RNA-FISH assays. PCA3 and PRUNE2
hybridized in the same nuclear foci (Fig. 1E and Fig. S2A). These
foci were completely depleted on treatment with RNase III,
which degrades only dsRNA, but not with RNase A, which de-
grades only single-stranded (ss)RNA (Fig. 1E and Fig. S2B),
indicating the formation of dsRNA from the physical association
of PCA3 and PRUNE2 pre-mRNA. Next, to evaluate whether
binding of PRUNE2 mRNA to PCA3 was required for the reg-
ulation of PRUNE2 levels, we assessed the effect of PCA3 on
exogenous mature PRUNE2 cDNA, which has no sequence
complementarity to PCA3 and therefore would be unable to
form a dsRNA. Indeed, ectopic PCA3 did not affect the exoge-
nous expression of PRUNE2 mRNA and protein (Fig. S3A). To
complement this finding, we also designed and expressed a
PRUNE2 construct that contains no protein-coding sequence but
is still fully complementary to PCA3 (termed intron6-PRUNE2)
and should therefore be able to bind PCA3 and possibly se-
quester it from PRUNE2. Consistent with this, overexpression of
intron6-PRUNE2 caused an increase in endogenous PRUNE2
mRNA in the cytoplasm and a concomitant reduction in the
nucleus (Fig. 1F). We confirmed a direct interaction between PCA3
and its corresponding antisense sequence (intron6-PRUNE2) by
using RNase-resistant assays and co-RNA-FISH in tumor cells
expressing both sequences (Fig. S3 B–E). These data suggest that
PCA3 binding to PRUNE2 pre-mRNA controls PRUNE2 levels.
ADARs Bind PRUNE2/PCA3 dsRNA and Regulate PRUNE2 Levels.
ADAR proteins are key regulatory enzymes for RNA editing
and sequestering of noncoding RNA sequences, such as introns
and untranslated mRNAs (5, 11–13), derived from the hybrid-
ization of retroinverted Alu elements (5, 13), with conversion of
adenosine-to-inosine (A-to-I) RNA editing after nuclear dsRNA
formation. Thus, we hypothesized that PCA3-PRUNE2 dsRNA
may be regulated by ADAR-mediated RNA editing. To test this
possibility, we used quantitative RT-PCR (qRT-PCR), co-RNA-
FISH, and RNA-ChIP. We found that endogenous PCA3 and
PRUNE2 pre-mRNAs colocalize to nuclear foci associated with
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Fig. 1. PRUNE2/PCA3 cloning, genomic structure, and colocalization. (A) Genomic context of intron/exon boundaries of PCA3 and PRUNE2 (GenBank ac-
cession no. FJ808772). Stars indicate missing or new exons; arrowheads indicate initiation (green) or stop (red) codons. Arrows indicate transcript orientation
(black, PCA3; red, PRUNE2). (B) RT-PCR with RNA from the PDX MDA-PCa-133 used to clone/sequence PRUNE2. (C) Analysis of PRUNE2 in LNCaP cells stably
expressing ectopic PCA3, PCA3-silenced, PRUNE2-silenced, or control. (D) qRT-PCR assays with primers (Table S1) amplifying PCA3 or different regions of
PRUNE2 in LNCaP cells with silenced or ectopic PRUNE2 and PCA3. (E) Combined RNase resistance and RNA-FISH analysis. Before hybridization, LNCaP cells
were treated with RNase A or RNase III. Hybridization was performed with specific probes against PCA3 and PRUNE2 transcripts. Nuclei are stained with DAPI.
Arrows indicate foci. Confocal images are shown (bar, 10 μm). Fig. 1E represents 100×magnifications (from Fig. S3A). (F) Expression effects of intron6-PRUNE2
on nuclear and cytoplasmic PCA3 and PRUNE2 levels in LNCaP cells. Shown data are mean ± SD.
Significance
Prostate cancer has an unpredictable natural history: While most
tumors are clinically indolent, some patients display lethal phe-
notypes. Serum prostate-specific antigen is the most often used
test in prostate cancer but screening is controversial. Treatment
options are limited for metastatic disease, hence the need for
early diagnosis. Prostate cancer antigen 3 (PCA3), a long non-
coding RNA, is the most specific biomarker identified and ap-
proved as a diagnostic test. However, its inherent biological
function (if any) has remained elusive. We uncovered a negative
transdominant oncogenic role for PCA3 that down-regulates an
unrecognized tumor suppressor gene, PRUNE2 (a human homolog
of the Drosophila prune gene) thereby promoting malignant cell
growth. This work defines a unique biological function for PCA3
in prostate cancer.
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ADAR proteins, which were sensitive to RNase III treatment
(Fig. 2 A–C and Fig. S4). PRUNE2/PCA3 dsRNA and ADAR1
formed a complex only when both RNA species were coex-
pressed; the corresponding signals for PRUNE2/PCA3 dsRNA
decreased after PCA3 or PRUNE2 silencing and increased with
ectopic expression of PCA3 in a UV-induced RNA-protein
cross-linking assay (Fig. 2D). To determine whether ADAR
proteins regulate PRUNE2 and PCA3 levels, we silenced ADAR1
in human tumor cells and found increased PRUNE2 mRNA and
protein levels (Fig. 2 E–G). We also found that ADAR-depleted
prostate cancer cells have increased cytosolic PRUNE2 and
PCA3 levels (Fig. 2 F and G and Fig. S5 A and B), revealing the
importance of ADAR members in the regulation of both genes,
consistent with functions of A-to-I editing in the regulation of non-
coding RNA species (14). To gain functional insight into the regu-
lation of PRUNE2 and PCA3, we established sensor/reporter assays
in which either PCA3 or the PCA3 antisense sequence (i.e., intron6-
PRUNE2) was fused to reporters to generate PCA3-luciferase or
intron6-PRUNE2-GFP. Reporter expression (by FACS and lumi-
nescence assays) showed that the coexpression of intron6-PRUNE2-
GFP plus PCA3 or intron6-PRUNE2 plus PCA3-luciferase results
in reduction of the corresponding reporter signals compared to
controls (Fig. S5 A–F). Thus, in addition to PCA3 regulating
PRUNE2 levels, and consistent with our earlier results, intron6-
PRUNE2 could also down-regulate PCA3 (Fig. 1F). Silencing of
ADAR1 or ADAR2 increased the reporter signals, confirming that
these enzymes are required for a coregulatory effect on both RNAs
(Fig. S5 E–H).
RNA Editing of PRUNE2 and PCA3 RNA Species. Our results thus far
have indicated that ADAR proteins associate with PRUNE2/
PCA3 dsRNA and regulate PRUNE2 and PCA3 levels via A-to-I
RNA editing. To test this possibility directly, we evaluated the
presence of A-to-I editing throughout the genomic coordinates
of PCA3 and its corresponding antisense pre-mRNA intron6-
PRUNE2 by RNA capture followed by next-generation sequenc-
ing. Although RNA editing is found largely within Alu elements,
we carefully filtered out repetitive elements (such as Alu sequences)
to avoid erroneous alignments. We showed that A > G/T > C
changes, which reflect A-to-I editing, were the most frequent
substitutions. Editing sites were distributed in intronic and exonic
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Fig. 2. PRUNE2/PCA3 colocalization to ADAR1. (A) RNA-ChIP and PCA3 and
PRUNE2 binding by qRT-PCR in LNCaP cells. (B) Combined RNase resistance and
RNA-FISH analysis. Before hybridization, LNCaP cells were treated with RNase A.
Hybridization and immunostaining were performed with specific probes and an
anti-ADAR1 antibody. (C) PCA3 and PRUNE2 binding to ADAR1 by RNA-ChIP.
(D) Hybridizationwith biotin-labeled oligomers (Table S1) against PCA3 and PRUNE2
in LNCaP cells after UV-induced RNA-protein cross-linking. Immunoblot against
ADAR1 is shown. (E and F) Evaluation of PCA3 and PRUNE2 expression in LNCaP
cells stably expressing two independent lentiviral ADAR1-shRNAs: immunoblots
against PRUNE2, ADAR1, and control protein (YY1) (E) and qRT-PCR (F) are shown.
(G) Cytosolic (C) and nuclear (N) RNA fractionation followed by qRT-PCR; specific
oligonucleotides served for amplification of nuclear pre-mRNA and cytosolic
mRNA of PCA3 and PRUNE2. Shown data are mean ± SD. *P < 0.05; **P < 0.01.
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Fig. 3. Functional role of RNA editing and androgen receptor (AR) activation
in PRUNE2/PCA3 regulation. (A and B) Identification, quantification, and dis-
tribution of A > G/T > C changes (features pathognomonic of A-to-I editing in
both strands of the PRUNE2/PCA3 dsRNA) analyzed after RNA capture followed
by high-throughput sequencing. Reads were aligned against hg19 of the re-
gion. Only nondbSNP variations indicated by at least three reads, and out of
repetitive elements were considered. (A) Distribution and percentage of all
possible alterations for the PCA3 genomic coordinates in LNCaP cells are shown.
(B) RNA editing map for LNCaP cells showing the precise location of each A > G
(green) or T > C (red) sites over PCA3 and intron6-PRUNE2 pre-mRNA species.
Each square represents one individual base from the PCA3 locus (23,112 nt).
Black borders delimit the bases of the four annotated exons (3,923 nt). Repeats
(RepeatMasker) are shown in gray (B). (C–E) Evaluation of PCA3 and PRUNE2
levels in LNCaP cells stably expressing two independent P54NRB-shRNA clones (C1
and C2) or controls (NT). Detection of PCA3 and PRUNE2 mRNA cytosolic levels
by RNA-FISH (C) and by qRT-PCR (D) are shown. Analysis of PRUNE2 expression
in LNCaP P54NRB-silenced cells or negative control is shown (E). (F) Analysis of
PRUNE2, AR, and phosphorylated AR (P-AR) expression in after concentration-
dependent androgen stimulation with R1881. Representative PAGE 3–8%
shown. (G) Relative mRNA expression levels of PCA3 and PRUNE2 transcript
under R1881 stimulation. (H) Relative mRNA expression of PRUNE2, PCA3, and
PSA (positive control) measured by qRT-PCR in LNCaP cells after dose-dependent
R1881 stimulation. (I) RNA-FISH analysis for PCA3 and pre-mRNA of PRUNE2 in
LNCaP cells under steroid-depleted conditions or after androgen stimulation.
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regions (Fig. 3 A and B), suggesting that a dsRNA hybrid is
formed between pre-mRNA species of both genes, as observed
in the RNA colocalization experiments. Given that the Dro-
sophila behavior human splicing (DBHS) protein P54NRB pref-
erentially binds to inosine-containing RNA (RNA-I) and
regulates gene expression, we investigated a potential role for
P54NRB and other DBHS proteins in regulating PRUNE2/PCA3.
Both, PCA3 and PRUNE2 pre-mRNA species associated with
P54NRB and the other two known mammalian family members (PSF
and PSPC-1) compared with negative control RNA by RNA-ChIP
(Fig. 2A) or combined co-RNA-FISH and immunofluorescence as-
says (Fig. S6). In addition, P54NRB-silenced prostate cancer cells had
increased levels of PCA3 and PRUNE2 mature RNA (Fig. 3 C and
D) and a concomitant increase of PRUNE2 protein levels relative to
controls (Fig. 3E). These data confirm that PRUNE2 and PCA3
RNAs undergo A-to-I editing and reveal a functional role for
DBHS proteins in their regulation.
Function of the PRUNE2/PCA3 Regulatory Axis in Prostate Cancer.
Androgen dependence and resistance to androgen deprivation
therapy are central to the biological and clinical features of prostate
cancer. Thus, we investigated whether AR activation regulates
PCA3 and PRUNE2 expression in androgen-dependent LNCaP
cells, which had lower PCA3 and higher PRUNE2 levels than an-
drogen-independent PC3 cells, when grown in steroid-depleted
serum (Fig. 3 F and G and Fig. S1C). Androgen stimulation of
LNCaP cells with a synthetic testosterone homolog (R1881) in-
duced a concomitant increase of PCA3 and decrease of PRUNE2
levels (Fig. 3 F–H), consistent with a report that PCA3 modulates
prostate cancer through AR signaling (15). We also observed an
increase in nuclear localization of PRUNE2 and PCA3 along with
androgen-induced responses (Fig. 3I). Thus, PRUNE2/PCA3 regu-
lation appears to be sensitive to AR activation, a molecular hall-
mark of prostate cancer. To further assess the functional role(s) of
the PRUNE2/PCA3 regulatory axis in prostate cancer, we generated
LNCaP cells (PRUNE2-expressing) or PC3 cells (PRUNE2-de-
ficient) stably expressing lentiviral constructs to silence or ec-
topically express PRUNE2 and PCA3 (Figs. S1 D–F and S3A).
PCA3 silencing or ectopic PRUNE2 expression decreased cell
proliferation and transformation in vitro; in contrast, PRUNE2 si-
lencing or ectopic PCA3 expression increased cell proliferation and
transformation (Figs. S7 and S8 A–C). Moreover, ectopic expres-
sion of PCA3 or antisense PCA3 (intron6-PRUNE2), which down-
regulates PCA3, respectively decreased and increased endogenous,
with no effect on exogenous mature PRUNE2 expression
lacking complementarity with PCA3 (Fig. 1C and Figs. S2A
and S8 D and E). Finally, we found that PRUNE2-deficient
PC3 cells stably expressing ectopic PRUNE2 had lower levels of
proliferation and transformation in vitro (Fig. S8 A and C).
These results are consistent with the negative regulation of
PRUNE2 by PCA3. We next investigated the downstream molec-
ular mechanism(s) through which PRUNE2 suppresses tumor
growth. PRUNE2 has three predicted functional domains (15):
BCH, DHHA2, and PPX1 (Fig. S9A). BCH inhibits RhoA, a
small GTPase that regulates the cytoskeleton, cell adhesion, and
migration (16), whereas DHHA2 interacts with Nm23-H1, a me-
tastasis suppressor (17). We found that endogenous PRUNE2
coimmunoprecipitates with RhoA and Nm23-H1 (Fig. S9 B–D).
Consistent with an inhibitory role for PRUNE2 in RhoA signaling,
PRUNE2 levels increased when LNCaP cells were grown in
nonadherent culture conditions (Fig. S9E), and the distribution of
PRUNE2 was inversely correlated with focal adhesion sites in
LNCaP-derived spheroids (Fig. S9 C and F). In addition, we ob-
served alterations in tumor cell adhesion and spreading, but no
effect on apoptosis (Fig. S10 A–D). We also noted decreased
adhesion, spreading, and migration of prostate cancer cells
upon PRUNE2 expression and the opposite effect on ectopic
expression of PCA3 or PRUNE2 silencing (Fig. S10 E–J).
These results, along with the established functions of interact-
ing proteins (16–18), suggest that PRUNE2 primarily decreases
tumor growth by inhibiting cell proliferation but also affects
adhesion, spreading, and migration. We subsequently extended
these results to human tumor xenograft models; LNCaP pros-
tate cancer cells stably expressing PRUNE2-shRNA, ectopic
PCA3, PCA3-shRNA, or controls were s.c. administered into
SCID mice. PRUNE2 silencing and ectopic PCA3 expres-
sion yielded markedly larger tumor xenografts than controls;
in contrast, tumor growth was greatly diminished relative to
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Fig. 4. PRUNE2/PCA3 functions in tumor xenograft models of prostate cancer. (A–D) Male SCID mice received SC injection of 5 × 106 LNCaP cells stably
expressing ectopic PCA3, PCA3-silenced, PRUNE2-silenced, or negative controls. Tumor growth was monitored and volume was measured (A). Tumors are
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controls when PCA3 was silenced (Fig. 4 A–C). Consistently, we
observed increased serum prostate-specific antigen (PSA)
concentrations in SCID mice that received LNCaP cells with
ectopic PCA3 expression or PRUNE2 silencing compared to
controls (Fig. 4D). In vitro, and also in tumor xenograft models,
expression of antisense PCA3 (intron6-PRUNE2), which se-
questers PCA3, decreased tumor growth in LNCaP but not in
PC3 cells (Fig. 4 E and F and Fig. S8 A and B). Further, ex-
pression of ectopic PRUNE2 in LNCaP cells administered in
SCID mice led to smaller tumors relative to controls (Fig. 4 G
and H), illustrating the tumor suppressor activity of PRUNE2.
Finally, silencing ADAR1, which increases PRUNE2 levels in
LNCaP cells, reduced tumor cell proliferation in vitro and in vivo
(Fig. 4 I and J and Fig. S11 A–C). These data show a functional
role for the PRUNE2/PCA3 regulatory axis in prostate cancer.
To explore the potential of clinical application of these findings,
we specifically targeted the PCA3 sense strand with a modified
siRNA (stealth RNAi-PCA3) serially administered to tumor-
bearing mice with established prostate cancer xenografts. We
observed tumor growth inhibition and serum PSA concentration
reduction relative to scrambled siRNA control (Fig. 4 K–N). These
results support the hypothesis that PRUNE2 expression has a
functional tumor suppressive role in prostate cancer and suggest
that the regulatory mechanism of PRUNE2 by PCA3 is a molecular
target for intervention.
Levels of PCA3 and PRUNE2 Inversely Correlate in Human Prostate Cancer
Specimens. To determine the clinical relevance of our findings, we
examined the expression of PCA3 and PRUNE2 in human prostate
cancer. First, we performed qRT-PCR analysis on tumor RNA
samples from prostate cancer patients (n = 48) and nonmalignant
areas of the prostate (n = 9). PRUNE2 mRNA expression was
detected more often in non–tumor-containing compared with the
tumor-containing areas of the prostate (Fig. 5A). In contrast, PCA3
mRNA levels showed the opposite pattern, with high expression
levels more frequently detected in tumors relative to nontumors,
consistent with its role in the negative regulation of PRUNE2. To
independently validate these clinical findings in silico, PRUNE2 and
PCA3 expression levels were evaluated through Oncomine (19) in a
large sample subset (n = 144) of primary nontreated prostate ma-
lignant tumors (n = 115) and nonmalignant prostate tissue (n = 29)
(20). Although no statistically significant correlation with survival
could be readily identified in this online dataset (20), a larger on-
going study is planned to fully address this question. Notably, to
minimize variation, samples from prostate cancer-derived cell lines,
metastatic lesions, and patients that received neoadjuvant therapy
were excluded from the analysis. We next used The Cancer Ge-
nome Atlas (TCGA) as another unrelated large dataset (n = 50
nonmalignant control prostate samples; n = 333 prostate cancer
samples) to validate the opposed expression between PRUNE2 and
PCA3. We found that low PCA3 levels correlated with high
PRUNE2 levels in nonmalignant control prostate samples and vice
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Fig. 5. PRUNE2/PCA3 expression in prostate cancer patient samples. (A) Analysis
of PRUNE2 and PCA3 mRNA levels in human prostate cancer samples (n = 48) vs.
nonmalignant prostate tissue (n= 9).Malignant (M) vs. nonmalignant (NM) control
is indicated. PSA served as a positive control for the qRT-PCR. In each case, P values
are for M vs. NM. (B) PCA3 and PRUNE2 expression levels of cDNA microarrays
from Oncomine. Blue, nonmalignant gland (n = 29); red, prostate tumor (n = 115).
Box-and-whisker plots with the data are presented with the horizontal lines within
boxes representing median signal intensity. Black lines depict the calculated slopes
linking to average intensity values. (C) RSEM. Normalized RNA-Seq data from
TCGA for PCA3 and PRUNE2mRNA in NM (blue) or M (red) from human prostate
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intensity. Black lines depict the calculated slopes linking to average intensity values.
(D) Human TMA of prostate cancer samples showing high-abundance of PRUNE2
in NM adjacent prostate tissue control compared withM. In each case, IHC staining
(i.e., % extent of expression in cells) was analyzed. Magnification, 20×. (E and F)
PRUNE2 estimated expression in the epithelium (E) or stromal (F) component of
the tumor samples (n = 145) with low-grade (n = 50) and high-grade (n = 95) vs.
NM adjacent control tissues (n = 145) in human prostate cancer specimens.
Mean ± SD is shown. **P < 0.01; ***P < 0.001.
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versa in prostate cancer samples (Fig. 5 B and C). Finally, we also
analyzed the protein expression pattern of PRUNE2 in a large
series of clinically annotated primary prostate cancer specimens
(n = 145), matched to adjacent histologically normal prostate tissue
(n = 145). In each case, immunohistochemical (IHC) staining was
compared between the epithelial and stromal cells within tumors to
the nonmalignant epithelial and stromal cells from adjacent non-
malignant areas of the same specimen (Fig. 5 D–F). We found a
higher abundance of PRUNE2 in nonmalignant vs. malignant
areas. The inverse correlation between the native expression of
PRUNE2 and PCA3 mRNA in clinical samples again supports a
meaningful role for their coregulation and tumor suppression in
human prostate cancer.
RNA Editing of PCA3 and PRUNE2 in Human Prostate Cancer Patients.
We ultimately analyzed specimens obtained from index prostate
cancer patients through RNA capture followed by next-generation
sequencing and detected the presence of RNA editing (Fig. 6A),
which was subsequently confirmed by classic Sanger sequencing (Fig.
6B) of genomic and cDNA clones from the same index patients.
Bioinformatics demonstrated A > G/T > C alterations as the most
frequent substitutions and data indicative of A-to-I editing in both
PCA3 and PRUNE2 pre-mRNA strands, with no clear editing hot-
spots identified in human tumor samples (Fig. 6C). The editing maps
provided for all patients show a similar distribution of alterations for
both RNA strands, suggesting the interaction of the pre-mRNAs of
both PCA3 and PRUNE2 transcripts (Fig. 6D).
Discussion
lncRNAs have recently emerged as central regulators of gene ex-
pression in various biological settings, but only a few have known
functional roles in human prostate cancer (1, 4, 5, 21–24). Here we
present extensive data that are consistent with an antisense intronic
lncRNA (i.e., PCA3) that acts by an ADAR-mediated RNA editing
mechanism to down-regulate its target gene (i.e., PRUNE2). In this
study, we establish the functional attributes of PCA3 as a trans-
dominant negative oncogene that inactivates the unrecognized tu-
mor suppressor gene PRUNE2 at the RNA level through an
ADAR-mediated mechanism; such a remarkable regulatory unit
located in a single genetic locus appears unique to human mam-
malian cells. Notably, the genomic region encompassing PRUNE2
contains several alternatively spliced isoforms (25–28), one of which
is ∼3 kb shorter than the PRUNE2 full-length sequence identified
here (presumably the canonical gene) and is found in human adult
nerve cells (25), with a related mouse brain-specific isoform (26);
thus, other tissue-specific isoforms with different functions may
perhaps exist. Tumor suppressor genes have long been shown to
affect cancer growth in the classic two-hit hypothesis (29, 30). More
recently, it became clear that even partial inactivation of tumor
suppressors contribute critically to tumorigenesis (31), as illustrated
here. In sum, we show a striking function for the clinically well-
established PCA3 marker that will lead to translational applications
in human prostate cancer.
Materials and Methods
Details can be found in SI Materials and Methods. PCA3 and PRUNE2 sequence
analyses were evaluated from cDNA microarray with Oncomine (19) or RNA-seq
data from TCGA; expression was calculated by RNA-Seq by expectation maxi-
mization (RSEM) (32). Cell fractionation, nuclear RNA analysis, and immuno-
precipitation/immunoblot were performed as previously described (13). siRNA
and shRNA were custom-ordered against PCA3 or PRUNE2 (Table S1), re-
spectively, and transfected into tumor cells (Ambion). Custom-ordered siRNAs
against PCA3 (Tables S1 and S2) were transfected into tumor cells with the
NeoFX transfection reagent (Ambion). RNA FISH and confocal microscopy RNAs
were performed to detect PCA3 and PRUNE2. Cell culture and functional assays
(cell proliferation, viability, adhesion, migration, soft agar colony formation, and
tumor cell-derived spheroids) were performed. Tumor-bearing mouse models
are described elsewhere (11). All animal experimentation was reviewed and
approved by the Institutional Animal Care and Use Committee of the University
of Texas M.D. Anderson Cancer Center (MDACC). Experiments with human
samples were reviewed and approved by the Clinical Research Committee and
by the institutional review board (IRB) at MDACC. All human specimens were
obtained after the patients provided written informed consent under an IRB-
approved experimental protocol. Total RNA samples purified from tumors from
human prostate cancer patients were also obtained from the Tumor Bank at
A.C. Camargo Cancer Center after IRB approval.
ACKNOWLEDGMENTS. This work was supported by National Institutes of
Health Grants CA90270 (to R.P. and W.A.) and CA95616 (W.K.C.), Angel-
Works, Gilson-Longenbaugh Foundation, Prostate Cancer Foundation (W.A.
and R.P.), Fundação de Amparo à Pesquisa do Estado de São Paulo, and
Associação Beneficente Alzira Denise Hertzog Da Silva (E.D-N.).
1. Walsh AL, Tuzova AV, Bolton EM, Lynch TH, Perry AS (2014) Long noncoding RNAs
and prostate carcinogenesis: The missing ‘linc’? Trends Mol Med 20(8):428–436.
2. Bussemakers MJG, et al. (1999) DD3: A new prostate-specific gene, highly overex-
pressed in prostate cancer. Cancer Res 59(23):5975–5979.
3. Wei JT, et al. (2014) Can urinary PCA3 supplement PSA in the early detection of
prostate cancer? J Clin Oncol 32(36):4066–4072.
4. Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861–874.
5. Fatica A, Bozzoni I (2014) Long non-coding RNAs: New players in cell differentiation
and development. Nat Rev Genet 15(1):7–21.
6. Geisler S, Coller J (2013) RNA in unexpected places: Long non-coding RNA functions in
diverse cellular contexts. Nat Rev Mol Cell Biol 14(11):699–712.
7. Machida T, et al. (2006) Increased expression of proapoptotic BMCC1, a novel gene
with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with favorable
prognosis in human neuroblastomas. Oncogene 25(13):1931–1942.
8. Clarke RA, et al. (2009) Newgenomic structure for prostate cancer specific gene PCA3within
BMCC1: Implications for prostate cancer detection and progression. PLoS ONE 4(3):e4995.
9. Lavin MF, Clarke R, Gardiner RA (2009) Differential expression of PCA3 and BMCC1 in
prostate cancer. Prostate 69(16):1713–1714, author reply 1715.
10. Salagierski M, et al. (2010) Differential expression of PCA3 and its overlapping
PRUNE2 transcript in prostate cancer. Prostate 70(1):70–78.
11. Lee YC, et al. (2011) BMP4 promotes prostate tumor growth in bone through os-
teogenesis. Cancer Res 71(15):5194–5203.
12. Bass BL (2002) RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem
71:817–846.
13. Chen L-L, DeCerbo JN, Carmichael GG (2008) Alu element-mediated gene silencing.
EMBO J 27(12):1694–1705.
14. Mallela A, Nishikura K (2012) A-to-I editing of protein coding and noncoding RNAs.
Crit Rev Biochem Mol Biol 47(6):493–501.
15. Ferreira LB, et al. (2012) PCA3 noncoding RNA is involved in the control of prostate-
cancer cell survival and modulates androgen receptor signaling. BMC Cancer 12:507.
16. Soh UJ, Low BC (2008) BNIP2 extra long inhibits RhoA and cellular transformation by
Lbc RhoGEF via its BCH domain. J Cell Sci 121(Pt 10):1739–1749.
17. Galasso A, Zollo M (2009) The Nm23-H1-h-Prune complex in cellular physiology: A ‘tip
of the iceberg’ protein network perspective. Mol Cell Biochem 329(1-2):149–159.
18. Basile JR, Gavard J, Gutkind JS (2007) Plexin-B1 utilizes RhoA and Rho kinase to
promote the integrin-dependent activation of Akt and ERK and endothelial cell
motility. J Biol Chem 282(48):34888–34895.
19. Rhodes DR, et al. (2004) ONCOMINE: A cancer microarray database and integrated
data-mining platform. Neoplasia 6(1):1–6.
20. Taylor BS, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell
18(1):11–22.
21. Cech TR, Steitz JA (2014) The noncoding RNA revolution-trashing old rules to forge
new ones. Cell 157(1):77–94.
22. Guttman M, et al. (2011) lincRNAs act in the circuitry controlling pluripotency and
differentiation. Nature 477(7364):295–300.
23. Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: Insights into func-
tions. Nat Rev Genet 10(3):155–159.
24. Ponting CP, Oliver PL, Reik W (2009) Evolution and functions of long noncoding RNAs.
Cell 136(4):629–641.
25. Iwama E, et al. (2011) Cancer-related PRUNE2 protein is associated with nucleotides
and is highly expressed in mature nerve tissues. J Mol Neurosci 44(2):103–114.
26. Arama J, et al. (2012) Bmcc1s, a novel brain-isoform of Bmcc1, affects cell morphology
by regulating MAP6/STOP functions. PLoS ONE 7(4):e35488.
27. Harris JL, et al. (2013) BMCC1 is an AP-2 associated endosomal protein in prostate
cancer cells. PLoS ONE 8(9):e73880.
28. Pan CQ, Low BC (2012) Functional plasticity of the BNIP-2 and Cdc42GAP Homology
(BCH) domain in cell signaling and cell dynamics. FEBS Lett 586(17):2674–2691.
29. Knudson AG, Jr (1971) Mutation and cancer: Statistical study of retinoblastoma. Proc
Natl Acad Sci USA 68(4):820–823.
30. Cavenee WK, et al. (1983) Expression of recessive alleles by chromosomal mechanisms
in retinoblastoma. Nature 305(5937):779–784.
31. Berger AH, Knudson AG, Pandolfi PP (2011) A continuum model for tumour sup-
pression. Nature 476(7359):163–169.
32. Li B, Dewey CN (2011) RSEM: Accurate transcript quantification from RNA-Seq data
with or without a reference genome. BMC Bioinformatics 12:323.
8408 | www.pnas.org/cgi/doi/10.1073/pnas.1507882112 Salameh et al.
Supporting Information
Salameh et al. 10.1073/pnas.1507882112
SI Materials and Methods
Reagents. Anti-BrdU (Millipore), anti−β-actin, anti−β-tubulin
(ECM Biosciences), ChIP grade anti-RED1, anti−Nm23-H1, anti-
RhoA (Abcam), anti-PRUNE2 (ProteinTech), anti-AKT, anti-
pAKT1, anti-pERK1/2, anti-p44/42 MAP kinase, ßanti-S6RP
(Cell Signaling Technology), anti-ADAR1 (Sigma or Abnova), and
anti-ADAR2 (Sigma) were commercially obtained. VEGF, basic
FGF (bFGF), EGF, and insulin-like growth factor (IGF) were
purchased from R&D Systems. An admixture (i.e., 10 ng EGF,
10 ng bFGF, 10 ng IGF, and 20 ng VEGF) supplemented with
heparin (5 U/mL) to a final concentration of 50 ng/mL served for
growth factor stimulation unless otherwise specified. Methyl-
trienolone (R1881; Perkin-Elmer) was used for androgenic stim-
ulation in steroid-deprived conditions as indicated. RNaseA and
RNase III (Invitrogen), DNaseI-RNase free (NEB), P54NRB, AR,
pAR, and charcoal-stripped FBS (Invitrogen) were commercially
obtained. Secondary antibodies were purchased from Jackson
ImmunoResearch or Invitrogen.
Cell Lines and Tissue Culture. Human tumor cell lines used (HeLa,
LNCaP, PC3, DU145, SF-268, SF-539, SNB-75, U-87, BT-549,
Hs587T, MCF-7, NCI-ADR-RES, NCI-H322M, A549K, EKVX,
NCI-H266, SK-MEL-28, UACC-257, OVCAR-8, SK-OV-3, ACHN,
HEK293, TK-10, KS1767, and COLO205) were grown in RPMI
containing 5% (vol/vol) FBS. Human epithelial (PrEC) and stro-
mal (PRSC) primary prostate cells, epithelial (RWPE-1 and
RWPE-2) and stromal (WPMY-1) transformed prostate cells, and
prostate cancer cells (VCaP and 22Rv) were cultured in optimized
medium (ATCC).
Bioinformatics and Sequence Analysis. Chromosomal locations, an-
notated transcripts, spliced expressed sequence tags, and se-
quence mapping were visualized on the Genome Browser from
theUniversity of California-SantaCruz (https://genome.ucsc.edu),
by using the latest version of the human genome assembly (hg19)
available. Conserved domain analyses were performed through
the Conserved Domain Database (www.ncbi.nlm.nih.gov/Structure/
cdd/wrpsb.cgi), and sequence alignments were made with either
ClustalW (www.ebi.ac.uk/Tools/msa/) or CLC bio (www.clcbio.
com). PCA3 and PRUNE2 expressions were evaluated from
cDNA microarray data of prostate cancer using Oncomine
(1) or RNA-Seq data from the TCGA Research Network
(cancergenome.nih.gov); for the latter, data were downloaded and
expression values were calculated through RSEM (2) using all
available samples.
Cloning and cDNA Generation. Total RNAs from tumor cell lines or
xenografts were isolated through the RNeasy kit (Qiagen), the
All-in-One kit (Norgen Biotek), or the TRIzol reagent (Life
Technologies). Total RNA samples from human normal tissues
(prostate, brain, liver, kidney, breast, lung, pancreas, spleen, and
testis) were commercially obtained (Stratagene). cDNAs were
synthesized by using the SuperScript III reverse transcriptase
(Invitrogen or Promega) from total RNA, with N15 random
pentadecamers, oligo dT primers, or specific oligonucleotides as
indicated (Table S1). PRUNE2 and PCA3 were amplified by RT-
PCR with KAPA HiFi DNA polymerase (KAPA Biosystems),
cloned into pENTR directional TOPO (Invitrogen), and fully se-
quenced. Verified coding sequences were reamplified and sub-
cloned into a pcDNA-DEST40 expression vector (Invitrogen).
shRNA-resistant PRUNE2 (PRUNE2 Ω shRNA) was created by
site-directed mutagenesis.
siRNA and shRNA. Custom-ordered siRNAs against PCA3 (Table
S1) were transfected into tumor cells using the NeoFX trans-
fection reagent (Ambion). PCA3-silencing experiments were
performed with retroviral pLKO.1 and human GIPZ vectors from
the RNAi Consortium (TRC) lentiviral shRNA library (Open
Biosystems) expressing specific shRNAs for human PRUNE2
(oligonucleotide ID TRCN0000121740, referred to as PRUNE2-
C1 and oligonucleotide ID TRCN0000144868, referred to as
PRUNE2-C2), human PCA3 (oligonucleotide ID V2LHS_ 24225,
referred to as PCA3-C1; and oligonucleotide ID V2LHS_24226,
referred to as PCA3-C2), human ADAR1 (oligonucleotide ID
TRCN0000050788, referred to as ADAR1-C1; and oligonucleo-
tide ID TRCN0000050790, referred to as ADAR1-C2 (Sigma),
human GIPZ ADAR2 (#RHS4287), and human TRIPZ lentiviral
inducible shRNAmir (#RHS4740; Open Biosystems). Lentivirus
particles for P54NRB-shRNA were purchased (TRCN0000074558
referred to as P54NRB-C1 and TRCN0000074559 referred to as
P54NRB-C2; Sigma). Stable clones were maintained under puro-
mycin selection. Validated nontargeting siRNA (Ambion) and
shRNA (Open Biosystems) sequences served as negative controls.
Customized Stealth chemically modified, HPLC-purified RNAi
sequences against PCA3 or scrambled controls were purchased
from Invitrogen.
Lentivirus Preparation. Lentiviral vectors (pCCLsin.PTT.PGK.
EGFP.Wpre, pMDLg/pRRE, pRSV-Rev, and pMD2.VSVG) were
used. Briefly, 293FT cells were transiently transfected (Lipofect-
amine 2000; Invitrogen) for 16 h, after which the lentiviruses were
harvested 24 and 48 h later and filtered through 0.22-μm pore
cellulose acetate filters. Recombinant lentiviruses were concen-
trated by ultracentrifugation for 2 h at 50,000 × g. Lentiviral vector
viability was confirmed by reporter gene expression and drug se-
lection. Cells were transfected with the FuGeneHD reagent (Ro-
che), and transgene expression was analyzed at 24, 36, 48, or 100 h
after transfection. Corresponding empty plasmids served as nega-
tive controls.
qRT-PCR and Northern Blotting. qRT-PCR analyses were performed
with SYBR-green in a 7500 Fast Real-Time PCR system (Applied
Biosystems). Gene expression levels were normalized against the
average Ct of three standard endogenous controls (P0 large ribo-
somal protein, β-glucuronidase, and TATA box-binding protein),
and the results were analyzed according to a standard ΔΔCt
method. Data were reported as fold induction; samples were nor-
malized onto their internal housekeeping genes followed by nor-
malization of each sample to its control. For Northern blotting,
customized LNA oligonucleotides (Exiqon) were used for PCA3
and PRUNE2 (Table S1). For retro-transcription, we designed
specific antisense primers for PCA3 or PRUNE2 that allowed
generation of specific cDNAs from corresponding pre-mRNA
overlapped regions that enabled the generation of strand-specific
cDNAs and PCR products for either PCA3 or PRUNE2. Am-
plified products were confirmed by sequencing.
Cell Fractionation and Nuclear RNA Analysis. Nuclear/cytoplasmic
RNA fractionation was performed (3). Tumor cells were grown in
fibronectin-coated plates. At 70% confluence, cells were har-
vested, centrifuged, and rinsed with ice-cold PBS. In brief, cell
pellets were resuspended by gentle pipetting in 200 μL lysis buffer
A [10 mM Tris (pH 8.0), 140 mM NaCl, 1.5 mM MgCl2, 0.1%
octylphenoxy poly(ethyleneoxy)ethanol (IGEPAL), and 2 mM
vanadyl ribonucleoside complex] and were incubated on ice for
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5 min. The same lysate sample served for total RNA extraction by
the TRIzol reagent (Invitrogen) and for centrifugation (1,000 × g
for 3 min at 4 °C), as well as to isolate the cytoplasmic fraction and
pellet the nuclei. Cell equivalent amounts of cytoplasmic and
nuclear RNA samples were used for nuclear retention analysis.
Nuclear/cytoplasmic ratios were normalized to GAPDH, HYOU1,
or SON RNA controls.
RNA FISH and Confocal Microscopy. To detect PCA3 and PRUNE2
RNAs, cells were fixed in 3.6% (vol/vol) formaldehyde for 3 min
at room temperature, followed by acetone:methanol 1:1 (vol/vol)
for 5 min at −20 °C. Cells were permeabilized in PBS containing
0.39 Triton X-100 and 5 mM vanadyl ribonucleoside complex
(Invitrogen) on ice for 5 min; vanadyl ribonucleoside complex
(an RNase inhibitor) was omitted if the RNase enzymatic activity
was to be determined. Cells were washed three times in PBS for
10 min and rinsed once in 2× saline sodium citrate (SSC) buffer
before hybridization. Hybridization was carried out using labeled
cy3, cy5, and 488 nm DNA-oligonucleotide probes in a moist
chamber at 37 °C overnight (ON). For colocalization studies after
in situ hybridization, cells were fixed for 5 min in PBS-containing
2% (vol/vol) formaldehyde. Standard immunofluorescence and
imaging were performed.
Immunoprecipitation and Immunoblot Analysis. Immunoprecipita-
tion assays were performed as previously described (3). Briefly, a
total of 3 × 106 subconfluent cells were starved for 36 h in RPMI
containing 0.25% BSA and 0.05% FBS. Cells were stimulated for
15 min at 37 °C with a growth factor admixture described above.
After washes with ice-cold PBS containing 0.1 mM sodium or-
thovanadate, cells were solubilized in 1 mL lysis buffer [50 mM
Tris(hydroxymethyl) aminomethane HCI (pH 7.4), 150 mM
NaCl, 1% Nonidet P-40 (Nonidet P-40), 0.25% sodium deoxy-
cholate, 1 mM EGTA, 1 mM EDTA, 2.5 mM sodium pyro-
phosphate, 1 mM sodium fluoride, 1 mM β-glycerophosphate,
1 mM sodium orthovanadate (Na3VO4) (pH 10.0), anti-protease,
and anti-phosphatase mixture; (Sigma)], collected, and incubated
on ice for 10 min. Cell lysates were centrifuged at 10,000 × g for
15 min, and supernatants were precleared for 1 h at 4 °C by in-
cubation either with 15 μL protein A- or protein G-agarose
(Roche). Precleared lysates were subsequently used for immu-
noprecipitation with specific antibodies as indicated. After in-
cubation, the solution was centrifuged at 1,000 × g for 4 min and
washed three times with 0.5 mL lysis buffer and once with ice-
cold PBS containing 1 mM Na3VO4. Immunoprecipitates were
separated by 3–8%, 4–12%, or 4% bis-Tris NuPAGE (Invitrogen)
as indicated, transferred to nitrocellulose membranes, and im-
munoblotted with specified antibodies.
RNA–Protein Complex Immunoprecipitation. Tumor cells at 70%
confluence were rinsed twice and scrapped into ice-cold PBS.
Cell pellets were resuspended in immunoprecipitation buffer
[50 mM Tris·HCl (pH 7.4), 150 mMNaCl, 0.05% IGEPAL, 1 mM
PMSF, and proteinase inhibitor mixture (Sigma)], subjected to two
rounds of gentle sonication, and centrifuged to obtain cell ex-
tracts. For RNaseA treatment, 200 μg/mL RNaseA was added to
cell extracts, and the admixture was incubated at 37 °C for 30 min.
For immunoprecipitation, RNaseA-treated and nontreated cell
extracts were precleared with 40 μL protein-A- plus protein-G-
agarose beads (Roche) and 2.5 μg mouse anti-ADAR1 antibody
or irrelevant isotype control antibody at 4 °C for 2 h, followed by
40 μL protein-A- plus protein-G-agarose beads for 30 min at room
temperature.
UV Cross-Linking and ChIP. Subconfluent cells cultured in complete
RPMI for 24 h underwent UV-mediated cross-linking, extract
preparation, and SDS/PAGE or standard immunoprecipitation.
For Western blot oligo-hybridization, specific 3′-biotinylated oli-
gonucleotides (Table S1) were used.
Cell Proliferation, Cell Viability, and Cell Death Assays. Cells were
seeded in 200 μL growth medium at a density of 5,000–10,000
cells per well onto E-Plates 96 (Roche). Cell attachment and
growth were monitored every 15 min for 48–72 h with real-time
cell electronic sensing (RT-CES) technology (Roche). The assay
system expresses impedance in arbitrary cell index (CI) units.
The CI at each time point is defined as (Rn-Rb)/15; where Rn is
the cell-electrode impedance of the well when it contains cells,
and Rb is the background impedance of the well with the me-
dium alone. Cell proliferation comparable data were measured
72 h later with the WST-1 cell proliferation reagent (Roche).
Cell viability was evaluated by the Trypan blue-exclusion meth-
odology. Cell death assays were performed through a standard-
ized cell death detection ELISA kit (Roche). In brief, cells were
cultured in complete RPMI medium for 24 h. After cell lysis, the
cytoplasmic fraction was prediluted to 1:10 (vol/vol) with in-
cubation buffer and tested for nucleosomes in the immunoassay
substrate reaction.
Cell Adhesion and Migration Assays. Cells were seeded in 200 μL
RPMI medium supplemented with 2.5% (vol/vol) FBS plus 50 ng
of a growth factor admixture (described above) at a density of
5,000–10,000 cells per well onto E-Plates 96 (Roche). Cell ad-
hesion was monitored every 15 min, during 4 h through RT-CES
technology (Roche). A 24-well in colorimetric format (CytoSelect;
Cell Biolabs) was used for cell migration assays. Briefly, a cell
suspension (1,000 cells) was placed in the upper chamber, and
RPMI medium containing 2.5% (vol/vol) FBS plus the growth
factor admixture was placed in the lower chamber and incubated
at 37 °C and 5% CO2 for 4 h. Cell migration was subsequently
quantified.
Cell Cycle Analysis. Cells were synchronized in RPMI containing
0.2% BSA and stimulated with 10% (vol/vol) FBS for 24 h.
Proliferating cells were labeled by administration of BrdU at 10 μM
for 1 h (Sigma-Aldrich). Cells were harvested by trypsinization,
washed in ice-cold PBS, and fixed in 100% ethanol for 30 min on
ice. DNA denaturation was achieved by incubation of fixed cells
in 2 N HCl containing 0.05% Triton X-100 for 30 min at room
temperature. Residual acid was neutralized with 0.1 M sodium bo-
rate (pH 8.5). Samples were incubated with an anti-BrdU mono-
clonal antibody, followed by cy-3−conjugated secondary antibody
anti-mouse IgG (Jackson ImmunoResearch Laboratories). Total
DNA content was measured with 50 μM propidium iodide (PI).
Flow cytometry analysis was performed in a FACS Canto II
System using the FACS Diva software (Becton-Dickinson).
Soft Agar Colony Formation Assay. Standard analysis of anchorage-
independent cell growth and colony formation was performed. In
brief, cells transduced with the indicated constructs were sus-
pended at either 5 × 103 or 105 cells per well in 2 mL of 0.35%
low-melting agarose in 35-mm culture dishes containing 0.7%
agarose base. Triplicates were prepared and evaluated for each
construct. Colonies were allowed to form at 37 °C under stan-
dard tissue culture conditions for 21–28 d. After incubation,
staining of the formed colonies with 0.005% crystal violet (CV)
enabled visual inspection, photographs, and optical density mea-
surements after CV solubilization.
Confocal Analysis of Tumor Cell-Derived Spheroids. Tumor spheroids
were prepared by growing 50–200 LNCaP cells in nonadherent
96-microwell culture dishes for 18 h in RPMI containing
10% (vol/vol) FBS. Spheroids were removed and cultured on
fibronectin-coated slides in RPMI containing 2.5% (vol/vol) FBS
plus a growth factor admixture (described above). Six hours
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later, spheroids were fixed, immunostained with the appropriate
antibody, and 3D analyzed for PRUNE2, RhoA, Nm23-H1, and
β-tubulin localization.
RNA-Capture Library Preparation and Large-Scale Sequencing Analysis.
RNA molecules derived from the PRUNE2/PCA3 locus were
captured and sequenced in large scale for a comprehensive
analysis of A-to-I editing. For the library preparation, mature and
immature RNA molecules derived from the PRUNE2 locus
(∼300 kb) were captured by using 120 nucleotide (nt) probes
designed for a 2× tiling coverage (eArray; Agilent). Captured
RNAs were used as templates for the construction of libraries
through the SureSelect RNA Target Enrichment for Illumina
Paired-end Multiplexed Sequencing kit and protocol (Agilent).
Libraries were sequenced by using a MiSeq instrument (Illumina)
generating >3 million 150-nt reads per sample (i.e., ∼450 million
bases sequenced per sample). Reads were aligned to the human
reference genome (hg19) with the Burrows-Wheeler Aligner
(BWA-0.6.1). Repetitive regions from RepeatMasker were masked,
and >400,000 on-target reads for each sample remained. After
removing variants present in dbSNP (release 137), all discrep-
ancies between the sample reads and hg19 (confirmed by at
least three independent sequence reads) were considered and
further analyzed through the CLC Genomics Workbench (ver-
sion 6.0.3). A detailed analysis of putative ADAR1- and ADAR2-
mediated editing (A > G/ T > C substitutions) was performed
over the locus of interest, including the mapping of putative ed-
iting sites, the determination of editing frequency (i.e., putative
edits per kilobase), and editing density (i.e., percentage of reads
showing the alteration).
RNA-Editing Analysis by Sanger Sequencing. Nuclear or total RNA
samples were isolated and subjected to three pulses of sonication
(300 Hz) to produce RNA fragments of 1,000–2,000 nt, followed
by DNaseI treatment. RNA samples were added to two different
minilibraries of specific primers (designed to cover intronic, as
well as exonic regions of PCA3 and the corresponding intron6-
PRUNE2), and the admixtures were heated to 99 °C for 10 min
and ice-chilled for 5 min. Specific cDNAs for PCA3 and
PRUNE2 were produced by reverse transcription with Super-
Script II/III (Invitrogen) by using primers designed to bind in-
tronic and exonic regions of PCA3 and the corresponding
intron6-PRUNE2. Resultant cDNAs were amplified by PCR
(850-1,000 bp) and subcloned in the TOPO vector, and in-
dividual single colonies were picked and amplified. The A-to-I
editing (reflected by A > G/T > C changes) frequency was es-
timated by Sanger sequencing of >100 individual clones con-
taining the expected inserts. As evidence of RNA editing, we
considered only non-dbSNP alterations located outside of re-
petitive elements (including Alus) and only those represented by
at least three distinct reads.
Tumor-Bearing Mouse Assays. PC3 and LNCaP cell lines were es-
tablished, each stably expressing ectopic PRUNE2, ectopic PCA3,
control vector, PCA3 silenced, PRUNE2 silenced, and control-
shRNA. In each case, stably expressing pool transduced cells and
their corresponding controls were allowed to grow for 48 h to reach
85% confluence. Afterward, paired test and control tumor cells
were counted, washed in serum-free medium, and resuspended to
a final concentration of 5 × 107/mL in serum- and phenol-free
basic RPMI medium. Cells were subsequently mixed in 50%
volume of phenol-free Matrigel (Becton Dickinson), and cell
suspensions (final volume of 200 μL) were administered s.c. in the
right flanks of male 6-wk-old SCID mice (Charles River). Tumor
xenograft growth was monitored serially over time. The MDA-
PCa-133 patient-derived xenograft (PDX) has been reported
elsewhere (4). Total RNA was obtained from an early tumor
passage and used to clone PRUNE2. All animal experimentation
was reviewed and approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of Texas M.D.
Anderson Cancer Center (MDACC).
Tissue Microarray and Immunohistochemistry. A human tissue micro-
array (TMA) was constructed from prostate cancer patients (n =
145) and consisted of intermediate- or high-risk tumors (Gleason
score ≥ 7, locally advanced ≥ pT2, peripheral zone tumors; n =
95) and low-risk tumors (Gleason score 6, peripheral zone tu-
mors, previously untreated, who underwent prostatectomy; n =
50). Areas representative of all histologic tumor patterns of the
Gleason grades were selected from the individual specimens. The
TMA consisted of 1,500 cores, and each individual patient was
represented by a set of 0.6-mm-diameter cores (median, 12;
range, 18–53). For IHC analysis, images in each core of the TMA
were acquired by the use of a BLISS imaging system (Bacus
Laboratories). A standard percentage system was used for assess-
ment of involvement (percentage of tumor cells exhibiting detect-
able staining). The extent of PRUNE2 protein expression was
determined in tumor epithelium vs. adjacent stromal tissue; TMA
slides were stained with an anti-PRUNE2/BMCC1 rabbit poly-
clonal antibody (ProteinTech Group) at a 1:70 dilution. The in-
tensity of staining was scored as absent, low, or high. An automated
stainer (DAKO) and standard 3,3-diaminobenzidine were used.
Tumor samples were clinically annotated and selected from a se-
rum and tissue bank supported by the National Cancer Institute
(NCI) Specialized Program of Research Excellence (SPORE) in
prostate cancer at MDACC. All human experimentation was re-
viewed and approved by the Clinical Research Committee (CRC)
and by the institutional review board (IRB) at MDACC. All hu-
man specimens were obtained after the patients provided written
informed consent under an IRB-approved experimental protocol.
Total RNA samples purified from tumors from human prostate
cancer patients were also obtained from the Tumor Bank at A.C.
Camargo Cancer Center after its IRB approval.
Statistics. We summarized PRUNE2 expression in the samples
by the use of standard descriptive statistics for continuous
variables or tabulations for categorical variables. The primary
analysis was based on the involvement score (extent of staining)
alone, which was treated as a continuous variable. Statistical
significance was determined by the appropriate tests. The non-
parametric Wilcoxon–Mann–Whitney test served to assess dif-
ferences in expression between high-grade, low-grade, and bone
metastatic cases and stromal and epithelial compartments. The
Student t test or Fisher’s exact test was used in the data analysis
for categorical variables as appropriate. To incorporate re-
peated measurements (e.g., TMA cores) from an individual
patient, mixed-effects models were fitted to allow estimates of
variability either within or among patients. The P values and
SDs were reported in the data analysis with independently re-
peated experiments. All reported P values are two-sided, and P <
0.05 was considered statistically significant. Analyses were done
with SAS for Windows (1999–2000; SAS Institute, release 8.1)
and S-PLUS 2000 (1988–2000; Insightful Corporation, release 3).
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Fig. S1. Expression of PRUNE2 and PCA3 transcripts and related constructs in human cells. (A) PRUNE2-related mRNA levels in a representative panel of human
tumor cell lines. Transcripts were amplified through qRT-PCR with a set of specific primers indicated in parentheses (Table S1). (B) Genomic scheme depicting
intron and exon boundaries of the locus. Arrows indicate orientation of transcripts (red, PRUNE2; black, PCA3). Representation of PRUNE2 pre-mRNA with the
location of primer sets (Table S1) targeted to different regions encompassing the PRUNE2 and PCA3 sequences. Boxes (brown) represent Northern blot (NB)
probes (NB probe 1, 5′-PRUNE2; NB probe 2, PRUNE2; Table S1) shown in H. (C) Relative mRNA expression of PRUNE2 and PCA3 in a panel of nonmalignant
prostate-derived cells and prostate cancer-derived cells. Relative expression levels were compared against a panel of standard endogenous controls (Materials
and Methods). Mean ± SD is shown. (D) Immunoblots probed with anti-PRUNE2 or anti-V5 epitope tag antibodies showing endogenous PRUNE2 expressed in
prostate cancer LNCaP cells and ectopic expression of PRUNE2 in prostate cancer PC3 cells (PRUNE2-deficient). A GFP-expressing vector served as a negative
control. (E) Immunoblotting analysis of whole cell extracts from LNCaP cells stably transduced with lentiviral shRNA constructs: two independent shRNA clones
against PRUNE2 along with a negative control (nontargeting) shRNA were used. (F) Changes in PCA3mRNA levels in prostate cancer LNCaP cells, from baseline
(control shRNA), ectopic PCA3 expression, or endogenous PCA3-silencing by two independent shRNA constructs (termed PCA3-shRNA-C1 and PCA3-shRNA-C2.
(G) Relative expression of PRUNE2 and PCA3 pre-mRNA levels in LNCaP cells stably expressing PCA3-shRNA or nontargeting shRNA control. (H) Northern blot
analysis of RNA extracted from LNCaP cells stably expressing constructs as indicated. Corresponding primers depicted in A and B are color-coded.
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Fig. S2. PRUNE2 protein expression in human prostate- and prostate cancer-derived cells and nuclear colocalization of PRUNE2/PCA3 RNA duplex.
(A) Evaluation of PRUNE2 protein expression by immunoblot in a representative panel (n = 9) of human prostate- and prostate cancer-derived cells (Materials
and Methods) stably transduced with either PRUNE2-shRNA, ectopic PCA3, or control constructs. (B–D) Prostate cancer LNCaP cells were subjected to either
RNase A or RNase III treatment followed by labeled oligonucleotide (Table S1) hybridization as described (Materials and Methods). PCA3-cy3 (located either in
PCA3 exon 4 for mature mRNA or in PCA3 intron 1 for pre-mRNA; as indicated) and PRUNE2-cy5 (located in PRUNE2 intron 6) oligomers were used. Pre-mRNA
of PRUNE2 (green) and mRNA of PCA3 (red) are shown. Yellow color (merge panels) indicates PCA3 and PRUNE2 colocalization within the nucleus (DAPI, shown
in blue). Labeled oligonucleotide-cy3 and -cy5 GFP probes served as negative controls (B). Ribonuclease digestion controls of the pre-mRNA (red) or mRNA
(green) for PCA3 and PRUNE2 are shown (C and D).
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Fig. S3. Effects of PCA3 expression on PRUNE2 coding sequence and nuclear colocalization of PRUNE2 pre-mRNA and PCA3. (A) Analysis of combinatorial
transfections in human prostate cancer PC3 cells (PRUNE2-deficient). Empty vector, V5-PRUNE2, intron6-PRUNE2, and ectopic PCA3 were used as indicated.
Immunoblots with either a V5-tag antibody or an anti-PRUNE2 antibody demonstrate that PCA3 levels have no detectable effect on exogenous PRUNE2
expression compared to controls (outlined in red). (B and C) LNCaP cells stably overexpressing PCA3. RNase-resistance assay on nuclear RNA (B) followed by
RT-PCR by using specific oligonucleotides for PCA3 and PRUNE2 pre-mRNA (Table S1). RNA from PC3 cells was used as negative control (C). (D) Cells were
subjected to co-RNA-FISH using labeled oligonucleotides for PCA3 (located in exon 4; red) and PRUNE2, in red (located in intron 6; green). (E) HeLa cells stably
coexpressing ectopic PCA3 and intron6-PRUNE2 RNA were subjected to co-RNA-FISH using labeled oligonucleotides for PCA3 (located in exon 4, red) and
PRUNE2 (located in intron 6, green). (D and E) Yellow color (merge panels) indicates PCA3 and PRUNE2 colocalization within the nucleolus (DAPI, shown in
blue). Representative images are shown. (Scale bars, 10 μm.)
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Fig. S4. Nuclear colocalization of PRUNE2/PCA3 RNA duplex with ADAR1/2. (A–D) LNCaP cells were subjected to either DNase or RNase treatment as indicated,
followed by oligonucleotide hybridization. Combined RNA-FISH and immunofluorescence with an anti-ADAR1 (A–C) or anti-ADAR2 (D) antibodies. Labeled
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nucleolus (DAPI, shown in blue). Representative images are shown. (Scale bars, 10 μm.)
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Fig. S5. Analysis PRUNE2 and PCA3 regulation through ADAR-mediated mechanisms. (A) RT-qPCR on fractionated RNA from cytosol (C) or nucleus (N) from
LNCaP cells stably expressing ADAR1-shRNA or negative control constructs. (B) Quality control of cytosolic and nuclear RNA-fractionation by agarose gel
electrophoresis after RT-PCR amplification. PRUNE2 and PCA3 pre-mRNA species are detected mostly in the nucleus as well as the controls HYOU1 and SON
(control nuclear mRNAs); in contrast, GAPDH mRNA (control cytosolic mRNA) is detected mostly in the cytosol. (C–E) HeLa cells stably expressing intron6-
PRUNE2-GFP were transduced with either PCA3 or control constructs. Cells were analyzed for reporter GFP expression by FACS (C) and by immunoblotting with
anti-GFP antibodies (D) after 24, 48, and 100 h. HeLa cells stably expressing intron6-PRUNE2-GFP, PCA3, ADAR1-shRNA, nontargeting shRNA control, or
negative control (empty) lentivirus were analyzed after 48 h for the reporter GFP expression (E). (F) Human tumor cell lines stably coexpressing PCA3-luciferase
(Luc) were transduced with intron6-PRUNE2-GFP or negative control expression vector. Tumor cells were lysed and luciferase activity was measured at 36 h
after transduction. *P < 0.05, **P < 0.01, ***P < 0.001. (G and H) Evaluation of PRUNE2 levels in LNCaP cells stably expressing ADAR1- or ADAR2-shRNA, and
control lentivirus. Quality control of two individual ADAR1- and ADAR2-shRNA constructs (G). Whole cell extracts from LNCaP cells expressing ADAR1- and
ADAR2-shRNA constructs were probed with antibodies against PRUNE2 and tubulin (H).
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Fig. S6. Colocalization of PRUNE2/PCA3 with P54NRB. LNCaP cells were subjected to RNase pretreatment as indicated followed by oligonucleotide hybrid-
ization and immunofluorescence as described (Materials and Methods). (A–C) Detection of PCA3-cy3 (located in exon 4, red) and PRUNE2-cy5 (located in intron
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Fig. S7. Function of PRUNE2/PCA3 in prostate cancer cells. (A) LNCaP cell proliferation in vitro after alteration of PCA3 and PRUNE2 levels or treatment with
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Fig. S8. Epistasis analysis of the functional interplay between PRUNE2 and PCA3 in human prostate cancer cells. (A) Tumor cell growth analysis in PC3 cells
stably expressing intron6-PRUNE2, ectopic PRUNE2, ectopic PCA3, intron6-PRUNE2 plus ectopic PCA3, PCA3-shRNA, PRUNE2-shRNA, or control shRNA con-
structs. (B) Tumor cell growth analysis in LNCaP cells stably expressing PCA3-shRNA, PRUNE2-shRNA, intron6-PRUNE2, V5-PRUNE2, or control constructs.
(C) Anchorage-independent cell colony growth in soft agar medium of PC3 cells stably expressing V5-PRUNE2 or control vector. In each experiment, mean ± SD
is shown. *P < 0.05, **P < 0.01, ***P < 0.001. (D) Immunoblots of extracts from LNCaP cells stably expressing PRUNE2-shRNA, PCA3-shRNA, ectopic PCA3,
intron6-PRUNE2, or control shRNA constructs. (E) Immunoblots of whole extracts from LNCaP cells stably transduced with V5-PRUNE2, ectopic PCA3, intron6-
PRUNE2, or control shRNA constructs. Antibodies against V5-tag or actin were used.
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Fig. S9. PRUNE2 domains, interactions, and colocalization with RhoA and Nm23-H1. (A) Predicted protein domains of PRUNE2 and putative interaction sites
with RhoA and Nm23-H1. Conserved domains are indicated in blue (PPX1), red (DHH and DHHA2), and green (BCH), and protein sequences are indicated in
gray. (B) PRUNE2 coimmunoprecipitation with RhoA and Nm23-H1. Starved LNCaP cell lysates were obtained after 10-min stimulation with a growth factor
admixture (GF+; Materials and Methods) or BSA (GF−). Immunoprecipitation was performed with an anti-PRUNE2 antibody. Both RhoA and Nm23-H1 co-
precipitated with PRUNE2 on growth factor stimulation. Total cell extracts before immunoprecipitation served as loading controls. (C and D) Immunostaining
and confocal microscopy analysis of the entire LNCaP-derived spheroids were reconstructed by merging the full Z-section series. Colocalization of PRUNE2 (red)
with RhoA (C); Nm23-H1 (D) is shown in green. DAPI, blue. Arrows indicate protein colocalization. (E) Immunoblots probed for PRUNE2 in LNCaP cell lysates
grown in either nonadherent or adherent conditions as indicated. (F) Immunostaining and confocal microscopy analysis of the entire LNCaP-derived spheroids
were reconstructed by merging the full Z-section series. Colocalization of PRUNE2 (red) and tubulin (green). DAPI, blue. Arrows indicate proteins colocalization.
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Fig. S10. Biological function of PRUNE2 in prostate cancer cells. (A–D) PRUNE2 complementation assay in LNCaP cells stably expressing either control shRNA
(A) or PRUNE2-shRNA (B) were transduced with an shRNA-resistant PRUNE2 (PRUNE2-shRNA) construct. In both cases, PRUNE2-shRNA expression resulted in a
decrease in LNCaP cell adhesion and spreading. LNCaP cells stably expressing either control shRNA (C) or PRUNE2 shRNA (D) were transduced with PRUNE2-
shRNA. In both cases, ectopic expression of PRUNE2-RNA did not result in significant changes in cell death. (E–J) Effects of PRUNE2 overexpression on prostate
cancer cell adhesion and migration. (E–G) LNCaP cells stably expressing PRUNE2-shRNA, control shRNA, or two independent PRUNE2-shRNA constructs were
evaluated for their capacity to adhere (E and F) and migrate (G) in the presence of RPMI containing 2.5% (vol/vol) FBS plus a growth factor admixture.
(H) LNCaP, DU145, and PC3 prostate cancer cells were transfected with PRUNE2, an unrelated tumor suppressor gene RASSF1A (as a positive control), or vector
alone as a negative control and analyzed for cell adhesion. (I and J) Effect of PCA3 overexpression on cell adhesion in LNCaP cells. Cells stably expressing PCA3,
control shRNA, or two independent PCA3-shRNA constructs per gene were evaluated for their capacity to adhere (I) and migrate (J) in the presence of RPMI
containing 2.5% (vol/vol) FBS plus a growth factor admixture.
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Fig. S11. Effects of ADAR1-silencing in prostate cancer cells. (A–C) Cell growth of LNCaP cells stably expressing ADAR1-shRNA or control shRNA. Cell pro-
liferation (A), cell doubling time (B), and anchorage-independent colony formation in soft agar (C) are shown. In each experiment, mean ± SD is shown. *P <
0.05, **P < 0.01.
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Table S1. Oligonucleotide and probe sequences
Oligonucleotide ID Sequence
PRUNE2 amplification
P2.rv 5′ CCAAAACGAAGTCTAACAGACA 3′
P2.fw 5′ ACCCCGCTCGTCTTCCTT 3′
PRUNE2- C1/C2 coding sequences subcloning
P2-1enter.fw 5′ CACCATGGAAGAATTTTTGCAACG 3′
P2-1enter.rv 5′ AGGCTTTTCTTTCAGCTTCAAGTC 3′
P2-2enter.fw 5′ CACCATGGAATCAGAGAAGATCTCAG 3′
P2-2enter.rv 5′ GAGAAGGTTACCTGAATCTCCTCC 3′
Primers for RNA CHIP
PRUNE2 118540.fw 5′ TTTACGTTCTGGGATACATGTGC 3′
PRUNE2 121974.rv 5′ AGATCCCTGGGAGAAATGCCCGGCC 3′
PCA3 ex3.fw 5′ AAGAAAGGCTGCTGACTTTACCATCTGAGGC 3′
PCA3 ex4.rv 5′ GATCTTGAGATGCTTCCCAGCCTGTTCACAG 3′
Primers for oligo hybridization (5′ biotinylated)
PCA3 ex4.rv 5′ GATCTTGAGATGCTTCCCAGCCTGTTCACAG 3′
PRUNE2.rv 5′ CTGTGAACAGGCTGGGAAGCATCTCAAGATC 3′
Tubulin.rv 5′ ATGCGCGAGATCGTGCACATCCAGGCGGGCCA 3′
5′-PRUNE2
P2st1.fw 5′ CCACGACATGGAAGAATTTTTG 3′
P2st1.rv 5′ GCGTTTGCTTCGATTCAGTTT 3′
P2st2.fw 5′ TCTCCATCTGACAGCTCCTTTA 3′
P2st2.rv 5′ CTCATCACCGAGCAACTGGCT 3′
PRUNE2
P2mid.fw 5′ GGAGACCCAGTTCAGTGCTC 3′
P2mid.rv 5′ TGTAAATGCTTTCAAGTCACTGGT 3′
2mid2.fw 5′ TCAGACGGTGAAATAAAAGTG 3′
P2mid2.rv 5′ AGGATCTCATCACAGCCAC 3′
P2mid3.fw 5′ AATCGAAGCAAACGCTTGGAG 3′
P2mid3.rv 5′ TGTAAATGCTTTCAAGTCACTG 3′
PRUNE2_BMCC1
P2end1.fw 5′ CGTTTATTTGCCGGTAGGAG 3′
P2end1.rv 5′ GCTCAGGCTCTTTGGTAGGA 3′
P2end2.fw 5′ GGGAAATGCTTTCACCACAG 3′
P2end2.rv 5′ CTCTTCAAAGGGGATGTCCA 3′
P2end3.fw 5′ TCAATAGCTTATCAGAACTCAGTGG 3′
P2end3.rv 5′ TCAACAGAACCATGAACCAGA 3′
PCA3
AS1.fw 5′ AGAAGCTGGCATCAGAAA 3′
AS1.rv 5′ CTGGAAATGTGCAAAAACAT 3′
AS2.fw 5′ TGGGAAGGACCTGATGATACA 3′
AS2.rv 5′ CCCAGGGATCTCTGTGCTT 3′
PSA AS.fw 5′ AGCATTGAACCAGAGGAGTTCT 3′
PSA AS.rv 5′ CCCGAGCAGGTGCTTTTG 3′
GAPDH AS.fw 5′ GAAGGTGAAGGTCGGAGTC 3′
GAPDH AS.rv 5′ TCAGAAGATGGTGATGGGATTTC 3′
B2M.fw 5′ AGCAGAGAATGGAAAGTCAAA 3′
B2M.rv 5′ TGCTGCTTACATGTCTCG 3′
HPRT.fw 5′ CTCAACTTTAACTGGAAAGAATGTC 3′
HPRT.rv 5′ TCCTTTTCACCAGCAAGCT 3′
Probes for FISH RNA
CY3-PCA3 Probe-A 5′ AGTTTAGGCAGCAGGGCCAGAATCCTGACCCTCTGCCCCGTGGTTATCTCC 3′
CY3-PCA3 Probe-B 5′ CCCTGGAAAGATCTTGAGATGCTTCCCAGCCTGTTCACAGATCCCCTGG 3′
CY3-PCA3 Probe-C 5′ TCTAAACTCTTATAATCAAATTACACTTTTAGTATTTGCTGTCTC 3′
CY3-PCA3 pre-mRNA 5′ GAATAAAATTCCAAACCCATTCCCATGGCCTACAGACCTCTG 3′
CY3-GFP Neg Ctl 5′ ATGGAGAGCGACGAGAGCGGCCTGCCCGCCATGGAGATCGAGTGCCGCATCACCGGCAC 3′
CY5-PRUNE2 5′ CCAGGGGATCTGTGAACAGGCTGGGAAGCATCTCAAGATCTTTCCAGGGTTATACTTACTAGC 3′
CY5- GFP Neg Ctl 5′ TTACGTCGCCGTCCAGCTCGACCAGGATGGGCACCACCCCGGTGAACAGCTCCTCGCCCT 3′
Primers used for the synthesis of RNA probes
T3BMCC1.fw 5′ ATCGAAATTAACCCTCACTAAAGGGAGCTGTCAGATGGAGAAATAAAAGTG 3′
T7BMCC1.rev 5′ ATCGATAATACGACTCACTATAGGGCACCAGGATCTCATCACAGCCA 3′
T3HESPCA3.fw 5′ ATCGAAATTAACCCTCACTAAAGGGTGGGAAGGACCTGATGATACA 3′
T7HESPCA3.rev 5′ ATCGATAATACGACTCACTATAGGGGAGGGTCCCTAGAGAGACACGAA 3′
T7GFP Neg ctl 5′ ATCGATAATACGACTCACTATAGGGGCTACTTGTACATTATTCTT 3′
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Table S1. Cont.
Oligonucleotide ID Sequence
Probes for Northern blot
LNA-DIG PRUNE2 (NB-probe 2) /5DigN/AGCAATCTGTCGTCTCGGCT/3Dig_N/
LNA-DIG BMCC1 (3′PRUNE2) /5DigN/TATCCTGAATCTCCTCCGTGA/3Dig_N/
LNA-DIG PRUNE2 (5′ PRUNE2 NB-probe 1) /5DigN/TGGTATGTTCAGCACTGGTAAA/3Dig_N/
ACTIN-DIG Probe Cytoplasmic RNA (Purchased from ROCHE).
Table S2. Primers for RT-PCR, PCR, cloning, and editing analysis of dsRNA PCA3/Intron6-PRUNE2
Primer name Forward sequence (5′→3′) Primer name Reverse sequence (5′→3′)
Intron6-PRUNE2-1 AGAAGAAATAGCAAGTGC PCA3-1 TCGGCTGCAGCCACACAA
Intron6-PRUNE2-2 GAAAACGATGCCATAGAA PCA3-2 CATTCAAAACAATTGAC
Intron6-PRUNE2-3 GGTTGCAGTGAGCCAAGA PCA3-3 TTTTTGAGGCAGAGTCT
Intron6-PRUNE2-4 TCTACCTCTCCCACCTCG PCA3-4 GGCAAGGTTAAGATTTC
Intron6-PRUNE2-5 ATGGCTATTCTCATCTTC PCA3-5 TCCTTGCTCTTTTACACC
Intron6-PRUNE2-6 ATTTAATCACAAATCACT PCA3-6 TATTTTAATGTAGCATAG
Intron6-PRUNE2-7 GTGCTGAGATTACAGGCG PCA3-7 CCTACAGAAATACAAGCA
Intron6-PRUNE2-8 GAAACTAACATTTCAACC PCA3-8 ATTGTTGCAATAAACCTA
Intron6-PRUNE2-9 ACAATGAGGAAGACTACG PCA3-9 AAAGTAGCCATTATTACC
Intron6-PRUNE2-10 TTGCTACGTAGTCTTGAA PCA3-10 TGGTTTCCTTTAAGAGTT
Intron6-PRUNE2-11 AGAATGGGAAGAAAGGTT PCA3-11 ATTACAGGAAGCCAGAT
Intron6-PRUNE2-12 CGATCCTCCCACCTGACCC PCA3-12 AAAAATTAACTGGGCATG
Intron6-PRUNE2-13 AAGAAAGGACTTTTTCACT PCA3-13 TCCCAAATTCTAAGACTC
Intron6-PRUNE2-14 AGACAATCTCACGTGCACA PCA3-14 GCTTACTGTCTTTACTGA
Intron6-PRUNE2-15 ACTCAGCGGAGATTCTCGGC PCA3-15 GGTGCAGTGGCAGATGTG
Intron6-PRUNE2-16 TGTTTTCTAGTCAGAGAGG PCA3-16 CTAGAACACAGCAAGCAT
Intron6-PRUNE2-17 AACTGAGAAATGGCATAACA PCA3-17 TATGAGATTGAATGATAA
Intron6-PRUNE2-18 TCCTGACTGTGGGCTCAGAT PCA3-18 TGAAACATTCATTATCC
Intron6-PRUNE2-19 GTGAACCCAGGAGGCAGAGC PCA3-19 GCTCTGTCGCCCAGGCTG
Intron6-PRUNE2-20 TAAACTTAAAAATTACTTTC PCA3-20 TGTATATAACCTATTTTA
Intron6-PRUNE2-21 TTTTTACAGCCTTGGGAAAG PCA3-21 GTAGTTGTCTTCATGTTTC
Intron6-PRUNE2-22 TATTGGCCAGGCTGGTCTTG PCA3-22 CCCAGCACTTTGGGAGGCT
Intron6-PRUNE2-23 TCCTGTTGTGGATATTTATT PCA3-23 ATTGGTAATGCTCACTTT
Intron6-PRUNE2-24 TAACTTGTAATTCCTTGAA PCA3-24 AGAGACAAGGAAGAGCTT
Intron6-PRUNE2-25 AGCTGGGGCTGTGCATCAGG PCA3-25 AGGGAATTCAAATTCTGG
Intron6-PRUNE2-26 CTTTACGTTCTGGGATAC PCA3-26 CTTTACGTTCTGGGATAC
Intron6-PRUNE2-27 AGAAGCTGGCATCAGAAAAA PCA3-27 CATTCAGTTAACAGTTTGGAAGG
Intron6-PRUNE2-28 TATGTGGGTTGGCATTCTTG PCA3-28 TTTACGTTCTGGGATACATGTGC
Intron6-PRUNE2-29 GGGAAGGACCTGATGATACA PCA3-29 CTGGAAATGTGCAAAAACAT
Intron6-PRUNE2-30 AGTCCGCTGTGAGTCT PCA3-30 GCCTCAGATGGTAAAGTCAGC
Intron6-PRUNE2-31 ATCGACGGCACTTTCTGAGT PCA3-31 CCCAGGGATCTCTGTGCTT
Intron6-PRUNE2-32 AAGAAAGGCTGCTGACTTTACCATCTGAGGC PCA3-32 CCATTTCAGCAGATGTGTGG
Intron6-PRUNE2-33 CTGTGAACAGGCTGGGAAGCATCTCAAGATC PCA3-33 AGATCCCTGGGAGAAATGCCCGGCC
Intron6-PRUNE2-34 CCGAGAAGCTGGCATCA PCA3-34 GATCTTGAGATGCTTCCCAGCCTGTTCACA
Intron6-PRUNE2-35 GCTGCAGCCGAGGGAGAC PCA3-35 TTTCAAATCTGTAATCCCGTTCAA
Intron6-PRUNE2-36 TGGTGGGAAGGACCTGATGA PCA3-36 TTAAAGGGGCTGGAAATGTGC
Intron6-PRUNE2-37 CCTTCTGGGCCCAACATTCT PCA3-37 GATCTTGAGATGCTTCCCAGCCTGTTCACAG
Intron6-PRUNE2-38 CCCATCCCTCCAGCCTTATC PCA3-38 AGATCCCTGGGAGAAATGCCCGGCC
Intron6-PRUNE2-39 TCATGCAGTGCAAATCCCCA PCA3-39 GCCCAGAAGGAACCGTAGAG
Intron6-PRUNE2-40 CCTCGCATTTGTGGGTTCTC PCA3-40 TTTGCTTCACATCCCAGGCT
PCA3-41 GAACCCACAAATGCGAGGTG
PCA3-42 GGCCAGAAGCTAGCATCCAT
PCA3-43 ACAAGGAGCCACTGGGTTTC
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